Real-world experience of pembrolizumab and lenvatinib in recurrent endometrial cancer: A multicenter study in Korea

•We report the real-world data of pembrolizuamb plus lenvatininb for treating recurrent endometrial cancer.•Pembrolizumab plus lenvatinib is effective in providing acceptable response rates in Korean patients.•More than half of the patients experienced dose reduction of levatinib but adverse events were manageable.